InCarda Therapeutics
PrivateLast Round
Series D
Jun 15, 2022
Total Funding Raised
$77.56M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
InCarda Therapeutics operates in Healthcare & Life Sciences and is based in West Jordan, Utah. Its latest recorded funding round was a Series D round in June 2022.
InCarda Therapeutics is a biopharmaceutical company that develops innovative inhaled therapies for the targeted treatment of cardiovascular conditions, including paroxysmal atrial fibrillation.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Medical Devices
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
InCarda Therapeutics Comparables
Compare InCarda Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| HUYA Bioscience International | 78% | |
| Acesion Pharma | 77% | |
| Philip Morris International | 73% |
For institutional investors. Book with your work email.
InCarda Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Jun 15, 2022 | ||||
| Series C | Oct 21, 2020 | ||||
| Series B | Nov 8, 2018 | ||||
| Series A | Apr 28, 2015 | ||||
| Private Placement | Dec 5, 2014 | ||||
Debt | Aug 28, 2013 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
InCarda Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Deerfield Management | Series B, Series C |
| Morningside Ventures | Series B, Series C, Series A |
| Innoviva | Series D, Series C |
| Asset Management Ventures | Series B |
| HealthCap | Series C, Series B |
| Morningside Group | Series B, Series C, Series A |
| Sofinnova Investments | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors increased 117% MoM.
- Jun 18, 2026
Monthly visitors grew 39% MoM.
For institutional investors. Book with your work email.
InCarda Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about InCarda Therapeutics's valuation, stock price, and market status.
Is InCarda Therapeutics a public or private company?
InCarda Therapeutics is a private company.
What is the current stock price of InCarda Therapeutics?
InCarda Therapeutics is a private company, so its shares have no public market price. Caplight tracks InCarda Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is InCarda Therapeutics worth (valuation)?
Valuation information for InCarda Therapeutics is not publicly available.
Can I buy InCarda Therapeutics stock?
InCarda Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was InCarda Therapeutics's last funding round?
InCarda Therapeutics's most recent funding round was Series D on June 15, 2022.
Who are the main investors in InCarda Therapeutics?
Key investors in InCarda Therapeutics include Morningside Ventures, Innoviva, HealthCap, Morningside Group, Sofinnova Investments.
Will InCarda Therapeutics IPO soon?
No public IPO plans have been announced for InCarda Therapeutics.
How can I track InCarda Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in InCarda Therapeutics's shares on secondary markets.